Literature DB >> 29375940

Visceroptosis and the Ehlers-Danlos Syndrome.

Stephen Kucera1, Stephen N Sullivan2.   

Abstract

The case of a patient with visceroptosis and Ehlers-Danlos syndrome hypermobility type (RDS-HT) is reported here. The literature on this unusual but probably under-recognized complication is reviewed.

Entities:  

Keywords:  ehlers-danlos syndrome; functional gastrointestinal disorders; visceroptosis

Year:  2017        PMID： 29375940      PMCID： PMC5773269          DOI： 10.7759/cureus.1828

Source DB:  PubMed          Journal:  Cureus        ISSN： 2168-8184


  10 in total

Review 1.  Visceroptosis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: presentation of a rare manifestation and review of the literature.

Authors:  Eyal Reinstein; Mark Pimentel; Mitchel Pariani; Stephen Nemec; Thomas Sokol; David L Rimoin
Journal:  Eur J Med Genet       Date:  2012-07-07       Impact factor: 2.708

Review 2.  Gastrointestinal disorders in joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type: A review for the gastroenterologist.

Authors:  A B Beckers; D Keszthelyi; A Fikree; L Vork; A Masclee; A D Farmer; Q Aziz
Journal:  Neurogastroenterol Motil       Date:  2017-01-13       Impact factor: 3.598

Review 3.  Gastrointestinal and nutritional issues in joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type.

Authors:  Marco Castori; Silvia Morlino; Giulia Pascolini; Carlo Blundo; Paola Grammatico
Journal:  Am J Med Genet C Semin Med Genet       Date:  2015-03       Impact factor: 3.908

4.  Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic.

Authors:  A D Nelson; M A Mouchli; N Valentin; D Deyle; P Pichurin; A Acosta; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2015-09-16       Impact factor: 3.598

Review 5.  Re-writing the natural history of pain and related symptoms in the joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type.

Authors:  Marco Castori; Silvia Morlino; Claudia Celletti; Giulia Ghibellini; Michela Bruschini; Paola Grammatico; Carlo Blundo; Filippo Camerota
Journal:  Am J Med Genet A       Date:  2013-11-06       Impact factor: 2.802

Review 6.  Increased Need for Gastrointestinal Surgery and Increased Risk of Surgery-Related Complications in Patients with Ehlers-Danlos Syndrome: A Systematic Review.

Authors:  Marie-Louise Kulas Søborg; Julie Leganger; Jacob Rosenberg; Jakob Burcharth
Journal:  Dig Surg       Date:  2016-12-09       Impact factor: 2.588

7.  Recurring and generalized visceroptosis in Ehlers-Danlos syndrome hypermobility type.

Authors:  Chiara Dordoni; Marco Ritelli; Marina Venturini; Nicola Chiarelli; Lidia Pezzani; Annalisa Vascellaro; Piergiacomo Calzavara-Pinton; Marina Colombi
Journal:  Am J Med Genet A       Date:  2013-03-26       Impact factor: 2.802

8.  Small fiber neuropathy is a common feature of Ehlers-Danlos syndromes.

Authors:  Daniele Cazzato; Marco Castori; Raffaella Lombardi; Francesca Caravello; Eleonora Dalla Bella; Antonio Petrucci; Paola Grammatico; Chiara Dordoni; Marina Colombi; Giuseppe Lauria
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

9.  Ehlers-danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations.

Authors:  Marco Castori
Journal:  ISRN Dermatol       Date:  2012-11-22

10.  Functional digestive symptoms and quality of life in patients with Ehlers-Danlos syndromes: results of a national cohort study on 134 patients.

Authors:  Jean-David Zeitoun; Jérémie H Lefèvre; Vincent de Parades; César Séjourné; Iradj Sobhani; Benoît Coffin; Claude Hamonet
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240
  10 in total
  1 in total

Review 1.  Hypermobile Ehlers-Danlos syndrome and disorders of the gastrointestinal tract: What the gastroenterologist needs to know.

Authors:  Phoebe A Thwaites; Peter R Gibson; Rebecca E Burgell
Journal:  J Gastroenterol Hepatol       Date:  2022-07-20       Impact factor: 4.369
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.